Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

EU2P · European programme in Pharmacovigilance and Pharmacoepidemiology

FP7Status: SIGNED1 September 200930 June 2016EU funding €3,708,225

The Eu2P training network in Pharmacovigilance and Pharmacoepidemiology will meet the needs of industry,regulatory authorities and academia at the European level. It will give access to a harmonised training programme that gathers complementary specialized and eminent European partners. The Eu2P consortium consists of course providers with aproven record including the University of Bordeaux (Eu2P coordinator), the Autonomous University of Barcelona, the Erasmus University Medical Center, the University of Utrecht, the University of Hert[ordshire, the University of Verona, the Karolinska Institute and the European Medicines Agency. It will deliver programmes in harmacovigilance and Pharmacoepidemiology for continuing education diploma, Master’s degree as well as PhD and a short course orientated towards risk communication. Targetedaudiences will be all those involved in the medicine evaluation processes including specialists from academia,industry and regulatory bodies as well as non-specialists (e.g. journalists, ethics committee members, patient organizations...). The Eu2P project is composed of one management work package (WP), one administrative WP and six programme topic WPs. This structure leaves open the addition of WPs by other partners. Moduleswill be developed in each programme topic WP to meet the needs of each type of course and target audience leading to WP cross-interaction. To facilitate access and flexibility (modular workload), the Eu2P programme will be based on English blended learning: a mix of face-to-face, e-Teaching and e-Learning courses. The first phaseof the project (1 year) will establish the Eu2P programme and the e-Teaching and e-Learning centre. The second phase (4 years) will deliver, evaluate and promote the training programmes. Long-term viability of the programme will be assured by the learning experience and the resulting quality of trained persons, the demand for these and the financial balance.

Consortium · 24 organisations

coordinator

F. HOFFMANN-LA ROCHE AG

CH

participant

UNIVERSITA DEGLI STUDI DI VERONA

IT · €36,219

participant

THE UNIVERSITY OF HERTFORDSHIRE HIGHER EDUCATION CORPORATION

UK · €261,084

participant

GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

UK

participant

UCB PHARMA SA

BE

participant

NOVARTIS PHARMA AG

CH

participant

ASTRAZENECA AB

SE

participant

Fundacio' Institut Català de Farmacologia

ES · €512,338

participant

AMGEN

BE

participant

ORION OYJ

FI

participant

UNIVERSITE DE BORDEAUX

FR · €2,327,327

participant

Bayer Pharma AG

DE

participant

AGENCE NATIONALE DE SECURITE DU MEDICAMENT ET DES PRODUITS DE SANTE

FR · €9,600

participant

H. LUNDBECK AS

DK

participant

BOEHRINGER INGELHEIM INTERNATIONALGMBH

DE

participant

KAROLINSKA INSTITUTET

SE · €9,600

participant

ALMIRALL SA

ES

participant

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

NL · €261,084

participant

SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT

FR

participant

UNIVERSITEIT UTRECHT

NL · €261,084

participant

NOVO NORDISK A/S

DK

participant

ELI LILLY AND COMPANY LTD

UK

participant

THE EUROPEAN MEDICINES AGENCY

NL · €29,889

participant

JANSSEN PHARMACEUTICA NV

BE

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.